Q-omics provides the consensus-scored LINC01108 profile across patient tissues and cancer cell-line models. LINC01108 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC01108 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, LINC01108 RNA expression shows 9,106 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRP, and TGCT as cancer lineages where LINC01108 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01108 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01108 survival associations across molecular data types. LINC01108 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01108 RNA expression–survival associations across cancer types. High LINC01108 expression shows unfavorable associations in ACC, READ, KIRP and COAD, but favorable associations in KIRC and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LINC01108 RNA expression.
This table summarizes LINC01108 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01108. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01108 shows lower tumor expression in KIRP, LUAD, KICH, KIRC and LUSC and higher tumor expression in LIHC. The KIRP box plot shows higher LINC01108 RNA expression in normal versus tumor tissue (log2 FC = −0.116, t-test p < 0.001).
This table shows molecular features associated with LINC01108 in patient tissues and cancer cell lines. In patient samples, LINC01108 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
